Binfloxacin is a topoisomerase inhibitor that was studied as an antibacterial agent.

Bimoclomol is the non-toxic heat shock protein (HSP) coinducer, which was shown to display multilateral protective activities against various forms of stress or injuries at the level of the cell, tissue or organism. Bimoclomol binds to HSF-1 and induces a prolonged binding of HSF-1 to the respective DNA elements. Bimoclomol reached the end of the Phase II clinical trial in a group of 410 patients with diabetic complications. Preclinical it was tested as a promising therapeutic agent against Diabetic neuropathies; Ischaemic heart disorders and other diseases.

Bifluranol (brand name Prostarex), a fluorinated bibenzyl anti-androgen was developed as a nonsteroidal estrogen and was studied for the treatment of benign prostatic hyperplasia. Besides, was shown that bifluranol inhibited 17 alpha-hydroxylase/C17-C20 lyase.

Azamethonium (known in Europe as pendiomid), a substance with the ganglia-blocking effect that was used in Europe to treat patients with acute pulmonary embolism. Information about the nowadays application of this drug is not available.

Scopinast (previously known as KA 398) was studied for the treatment of asthma and allergic seasonal. However, the further development of the drug was discontinued.

Gemcadiol is a lipid-regulating compound that was first described in 1977 in a study with hyperlipoproteinemia patients. It was concluded to be an effective antilipemic agent that is very well tolerated. Another study, conducted in 1986, showed that the compound was non-toxic in rodents, and decreased blood cholesterol. Also, liver weights were increased. Monkeys given 25 to 300 mg/kg gemcadiol for 13 weeks had slightly decreased serum cholesterol and slightly increased serum creatine phosphokinase. No effects on fetus/embryo in pregnant animals administered gemcadiol was observed in this study. No newer publications exist for this compound.

Bolenol is a synthetic anabolic steroid that was never marketed.

Tryparsamide is an arsenic compound with activity against Spirochaetes bacteria. Tryparsamide is used in the treatment of syphilis and African sleeping sickness. For decades Tryparsamide remained the standard treatment for trypanosomiasis. Tryparsamide has two remarkable properties: first, it increases the resistance of the individual by improving his general physical status; and, second, the high penetrability for nervous tissue which it possesses may increase the potential spirocheticidal action of the drug.